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Although the intrinsic antiviral cell defenses of many
kingdoms utilize pathogen-specific small RNAs, the
antiviral response of chordates is primarily protein
based and not uniquely tailored to the incoming
microbe. In an effort to explain this evolutionary
bifurcation, we determined whether antiviral RNAi
was sufficient to replace the protein-based type I
interferon (IFN-I) system of mammals. To this end,
we recreated an RNAi-like response in mammals
and determined its effectiveness to combat influ-
enza A virus in vivo in the presence and absence
of the canonical IFN-I system. Mammalian antiviral
RNAi, elicited by either host- or virus-derived small
RNAs, effectively attenuated virus and prevented
disease independently of the innate immune
response. These data find that chordates could
have utilized RNAi as their primary antiviral cell
defense and suggest that the IFN-I system emerged
as a result of natural selection imposed by ancient
pathogens.
INTRODUCTION
The cellular response to virus infection is of fundamental impor-
tance for survival and can differ dramatically within the tree of
life. Prokaryotes defend themselves against virus infection
through the utilization of clustered regularly interspaced short
palindromic repeats (CRISPR), which provides a small path-
ogen-specific RNA template to guide a Cas nuclease toward
the incoming virus (Barrangou et al., 2007; Wiedenheft et al.,
2012). Similarly, many eukaryotes use small RNAs to target
virus (Ding and Voinnet, 2007; Hutva´gner and Zamore, 2002).
Like CRISPR, the antiviral RNAi system relies on the generation
of pathogen-derived small RNAs to provide specificity to a
nuclease, in this case, a member of the Argonaute (Ago) family
(Ding and Voinnet, 2007; Hutva´gner and Zamore, 2002). In this
antiviral defense mechanism, an RNaseIII nuclease called Dicer1456 Cell Reports 13, 1456–1466, November 17, 2015 ª2015 The Auis responsible for processing viral RNA into short 21- to
24-nucleotide fragments called short interfering RNAs (siRNAs),
which are subsequently loaded into an Ago-containing, RNA-
induced silencing complex (RISC) (Ding and Voinnet, 2007).
Curiously, whereas chordates have retained much of the small
RNA machinery to enable an antiviral RNAi response, this activ-
ity is seemingly limited to plants, arthropods, and nematodes
(Cullen et al., 2013). In place of RNAi, chordates utilize a
small-RNA-independent, protein-based defense called the
type I interferon (IFN-I) system as the major antiviral cellular de-
fense (Platanias, 2005). In this system, cellular recognition of
viral RNA culminates in the transcriptional activation of a family
of IFN-I genes, cytokines that induce the subsequent upregula-
tion of hundreds of IFN-I-stimulated genes (ISGs), which work
together to inhibit the cellular processes required by the virus
to replicate and spread (Platanias, 2005).
Interestingly, chordates do utilize a form of RNAi to target
transposable elements through the generation of a class of short
RNAs known as PIWI-interacting short RNAs (piRNAs), but this
activity is limited to vertebrate germ cells (Aravin et al., 2007).
Whereas some experimental results support the notion that
pluripotent cells also elicit a small-RNA-mediated antiviral
response, evidence for such activity is lacking fromdifferentiated
cells (Cullen et al., 2013; Li et al., 2013; Maillard et al., 2013). In
fact, ablation of Dicer expression from mammalian fibroblasts
has been investigated and found to have no impact on virus repli-
cation levels with the exception of those viruses that produce
their own miRNAs (Bogerd et al., 2014a). Moreover, evidence
is mounting that the IFN and RNAi responses may be incompat-
ible with each other. Stem cells have been shown to process
double-stranded RNA (dsRNA) and not generate IFN-I in
contrast to differentiated cells that do not generate siRNAs but
instead produce high levels of IFN-I (Wang et al., 2014). The
idea that these two systems are mutually exclusive with each
other is also supported by the fact that the IFN-I-mediated anti-
viral response shuts down the RISC, and expression of anti-
viral Dicer induces the IFN-I response (Girardi et al., 2015; Seo
et al., 2013). Whereas it remains controversial as to whether
stem cells can employ a piRNA-independent antiviral RNAi
defense, it is clear that the dominant intrinsic response to virus
infection in mammals is IFN-I based (Backes et al., 2014).thors
Figure 1. Determining miRNA-Mediated
Silencing Potential
(A) Gaussia luciferase activity from 293T cells co-
transfected with a vector expressing miR124
(p124) and a luciferase reporter containing a single
miR-124 site with complementarity ranging from
10 nt (10x1T) to 20 nt (20x1T). Renilla luciferase was
used to control for transfection efficiency. Error
bars represent SD; *p < 0.05.
(B) As described in (A), where the Gaussia lucif-
erase construct had two sites of either 16 or 20 nt of
complementarity.
(C) Western blot of protein derived from MDCK or
MDCK-124 cells infected with IAV (MOI = 0.01)
containing two or four target sites described in (A).
Top two panels denote NP and actin from MDCK
cells; bottom two panels depict the same from
MCDK-124 cells.
(D) Virus titers derived from multi-cycle growth
curves in MDCK or MDCK-124 cells treated with
the viruses described in (C). Error bars represent
SD; *p < 0.05.
(E) Flow-cytometry-based determination of MDCK
and MDCK-124 levels following mock infection or
treatment with the scrambled (Scbl) or miRNA-
targeted (Targeted) virus at 72 hpi.Collectively, these data suggest that IFN-I may have replaced
a small-RNA-mediated antiviral defense at some point in evolu-
tion. Whereas our understanding of the long arms race between
chordate hosts and their ever-present pathogenic neighbors re-
mains far from complete, data from chickens suggest that the
IFN system arose before the divergence of mammals and birds,
350 million years ago (Hedges et al., 1996). This framework is
further supported by fish, which also generate IFN-I following
virus infection (Langevin et al., 2013). Moreover, as the biology
of DNA recombination to diversify immune receptors arose in
ancestors of jawed vertebrates, the utilization of IFN-I in fish
allows us to infer that this defense system appeared prior to
the evolution of the more-sophisticated innate and adaptive im-
mune responses observed in mammals (Zhang and Gui, 2004).
The basis for why chordates seemingly abandoned RNAi in place
of IFN-I remains unknown.
In an effort to test whether RNAi could function as the
mammalian antiviral defense system, we set out to reconstitute
this environment by exploiting the presence of endogenous
microRNAs (miRNAs) and repurpose them to be virus-specific
siRNAs (tenOever, 2013). To this end, we incorporated
species-specific miRNA targets into a non-coding region of
influenza A virus (IAV) and characterized the virus in the
presence and absence of an IFN-I response. These data found
that small-RNA-mediated silencing elicited a potent inhibition
of virus infection that resulted in strains that could be attenu-
ated by more than five logs. Moreover, we could induce
small-RNA-mediated virus attenuation by generating strains
that produced virus-derived siRNAs. In all, we demonstrateCell Reports 13, 1456–1466, Nothat RNAi is an effective antiviral
strategy in mammals and suggest an
evolutionary event may have causedthe transition from RNAi to IFN-I as either system could have
functioned in chordates.
RESULTS
Defining the Durability of miRNA-Mediated Virus
Targeting
We and others have demonstrated that mammalian viruses
can be effectively silenced by introducing complementary tar-
gets of host miRNAs into the viral genome (Barnes et al.,
2008; Kelly et al., 2008; Langlois et al., 2012; Perez et al.,
2009; Pham et al., 2012). In an effort to address the durability
of this surrogate RNAi response, we first set out to define the
minimal complementarity required to induce silencing. To this
end, we generated luciferase constructs containing a miR-124
target site in the 30 UTR of the mRNA. miR-124 is a neural-spe-
cific miRNA of 20 nucleotides (nt) that has been implicated in
influencing host splicing (Makeyev et al., 2007). Incorporation
of one miR-124 target site, composed of 20 nt of perfect
complementarity, into the 30 UTR of Gaussia luciferase can
successfully silence greater than 80% of its activity following
exogenous expression of this neuronal miRNA (Figure 1A). In
contrast, when the target was composed of 14 nt or less of
complementarity, repression was completely lost, suggesting
the potency of silencing was directly proportional to the
strength at which the cognate miRNA could engage its target.
In agreement with this, target sites of 17 nt, 16 nt, and 15 nt
(measured from the 50 end of miR-124) demonstrated a clear
relationship that correlated binding strength to silencingvember 17, 2015 ª2015 The Authors 1457
efficiency (Figure 1A). Interestingly, comparing one versus two
target sites did not impact overall silencing potential in the
context of this biological readout (Figure 1B).
Drawing upon these results, we generated IAV strains contain-
ing miR-124 target sites with 20 or 16 nt of complementarity in
the 30 UTR of the nucleoprotein (NP) segment; these target
lengths represent perfect binding sites that would be generated
in the context of a bona fide RNAi response or the minimal site
length required to maintain silencing, respectively (Figure 1A).
We reasoned that including these two distinct small-RNA-target-
ing site lengths would allow us to evaluate the emergence of
escape mutants. Furthermore, despite only needing a single
target site to achieve potent silencing of an artificial luciferase re-
porter assay, we incorporated either two or four sites to ascertain
whether the abundance of targets was significant in the context
of virus infection. These viruses are referred to as 16x2, 16x4,
20x2, and 20x4 to denote the extent of complementarity and
number of target sites, respectively (Figure 1C). Furthermore,
we generated a control virus (Scbl), which contained a scram-
bled UTR of identical length and A/U composition to the miR-
124 target sites. To determine the impact of lengthening
the 30 UTR of NP, we compared wild-type virus (A/Puerto
Rico/8/34 or PR8) to our Scbl virus at the level of replication
and protein production. These data demonstrated that IAV and
IAV-Scbl showed no discernable difference that could be asso-
ciated with themodified segment as both replicated to levels be-
tween 107 and 108 plaque-forming units (pfu)/ml and generated
robust levels of NP (Figures S1A and S1B). Next, we chose to
compare our Scbl virus to 16x2, 16x4, 20x2, and the 20x4 engi-
neered strains in the presence and absence of miR-124. To this
end, we developed a Madin-Darby canine kidney (MDCK) cell
population expressing miR-124 (MDCK-124) to allow us to
compare replication in a model system that differed only in the
expression of a single miRNA. Northern blot of MDCK and
MDCK-124 cells demonstrated robust production of the desired
miRNA (Figure S1C). Consequently, whereas virus replication of
the Scbl, 16x2, 16x4, 20x2, and 20x4 strains demonstrated
robust NP expression and titers of 107pfu/ml in MDCK cells,
virus administration of MDCK-124 cells produced no detectable
NP and a precipitous drop in titers ranging from 102 to 104pfu/ml
in all but the control untargeted strain (Figures 1C and 1D). Inter-
estingly, in the context of virus infection, we note that attenuation
increased with the number of target sites but was not signifi-
cantly different between a target of complete complementarity
versus one of only 16 contiguous bases.
In an effort to determine whether virus infection could rapidly
escape targeting and thus explain the lack of mammalian anti-
viral RNAi, we passaged the aforementioned viruses in MDCK-
124 cells. However, after approximately ten passages, we
were unable to isolate virus, suggesting a lack of escape variants
(data not shown). Therefore, we next infected co-cultures of
MDCK and MDCK-124 cells at an approximate ratio of 3:1,
respectively, to determine whether the capacity to replicate in
the absence of small-RNA-mediated selection would result in
the emergence of escape variants. Interestingly, this experi-
mental methodology also failed to generate escape mutants
but instead resulted in the selective death of MDCK cells and
the generation of an MDCK-124 population majority in just1458 Cell Reports 13, 1456–1466, November 17, 2015 ª2015 The Au72 hr (Figure 1E). Taken together, these results illustrate the po-
tency of RNAi and suggest that small RNA targeting can be
achieved with as little as 16 nt of complementarity.
Self-Targeting Demonstrates a Lack of NS1 Antagonism
and RNAi Potency
Whereas the inability to generate an escape mutant may illus-
trate the potency of the RNAi system, this phenotype could
also be explained by the reported antagonistic RNAi activity of
NS1 (Hutva´gner and Zamore, 2002; Li et al., 2004). Alternatively,
as exploiting host miRNAs provides the cell with the ‘‘antiviral
siRNAs’’ prior to infection, the kinetics of this model system,
coupled to the incorporation of multiple target sites, may impose
a greater selective pressure as would be observed during a bona
fide RNAi response where the siRNAs are generated following
pathogen recognition.
To better discern between these distinct possibilities, we
generated a self-targeted IAV strain that expressed an siRNA
from the NS segment (encoding wild-type NS1) and targeting
the ORF of the NP segment at just a single site (Figure 2A). As
prior studies had already established that miRNA insertion did
not inherently impact IAV biology (Benitez et al., 2015; Varble
et al., 2010), we reasoned this virus design would behave in
one of two ways. Either the engineered virus would fail to self-
target given the expression of wild-type NS1 or the kinetics of
siRNA synthesis or we would force the emergence of an escape
mutant through eithermutation of the hairpin or the target site. To
this end, we infected A549 cells and performed small-RNA north-
ern blotting. The results showed that the virus effectively gener-
ated the artificial miRNA against NP (herein referred to as siNP;
Figure 2B). Infection of wild-type or Dicer-deficient fibroblasts
(termed NoDice cells; Bogerd et al., 2014b) with a control virus
expressing miR-124 (IAV-si124) or the self-targeted virus (IAV-
siNP) showed that the self-targeted virus was dramatically atten-
uated in wild-type cells, but not the absence of Dicer, as
evidenced by NP protein levels (Figure 2C). Furthermore, IAV-
siNP demonstrated more than a 10-fold attenuation within
48 hr of infection compared to IAV124 both in vitro and in vivo,
at which time escape mutants emerged (Figures 2D, 2E, and
S2A). Sequencing of plaque-purified variants from self-targeted
virus growth curves identified a mutant containing a large dele-
tion in the artificial miRNA responsible for the NP siRNA, herein
referred to as IAV-siNP Mutant (Figure 2E). Northern blot of
IAV-siNP Mutant corroborated that this deletion terminated the
production of siNP and restored levels of WT replication (Figures
2F and 2G). Interestingly, we were unable to identify any viruses
that mutated the NP target in the ORF, despite the presence of
only a single site.
In an effort to determine how much time the host cell would
have to generate a successful RNAi response, we next trans-
fected cells with plasmids expressing either miR-124 or the
siNP at 3, 6, 12, or 24 hr prior to infection to determine the degree
of attenuation as it relates to the availability of the virus-specific
siRNA. As transfection time does not equate to the immediate
production of miRNAs, we independently analyzed uninfected
samples by northern blot to estimate the levels of miR-124 or
siNP at the time of inoculation. These data found that miR-124
and siNP were clearly visible by small RNA northern blot bythors
Figure 2. Self-Targeting IAV Demonstrates
the Selective Pressure Imposed by miRNA-
Mediated Silencing
(A) Schematic depicting a self-targeted virus pro-
ducing a siRNA against the NP segment (siNP).
(B) Northern blot of RNA derived from MDCK cells
infected (MOI = 1) with IAV-siNP or IAV-si124. Top
panel depicts siNP, and lower panel shows U6 as a
loading control.
(C) Western blot of extracts derived from 293T or
NoDice cells infected (MOI = 0.1) with IAV-siNP or
IAV-si124 for 12 and 24 hpi. Panel depicts NP, NS1,
and actin as a loading control.
(D) Multi-cycle growth curve in MDCK cells infected
with the viruses described in (B). Supernatants were
collected at 12, 24, 36, and 48 hpi and plaqued on
MDCK cells. Error bars represent SD; *p < 0.05.
(E) Schematic depicting the hairpin in the parental
virus (top) and the mutant virus (bottom).
(F) Northern blot in MDCK cells infected (MOI = 1)
with WT IAV and the viruses described in (D). Top
panel depicts siNP, and lower panel shows U6 as a
loading control.
(G) Multi-cycle growth in MDCK cells with the
viruses in (F). Supernatants were collected and
plaqued on MDCK cells. Error bars represent SD;
*p < 0.05.12 hr posttransfection (Figure S2B). Comparing miR-124 and
siNP signal intensity to the ubiquitous miR-93 loading control,
we estimate that plasmid transfection induces approximately
100–1,000 copies/cell within 12 hr based on the average quanti-
fication of other constitutively expressed miRNAs (Bissels et al.,
2009). Cells infected under these same conditions found only
samples transfected 12 or 24 hr prior to virus treatment success-
fully induced attenuation (Figure S2C). As transfection 6 hr prior
to infection failed to target virus, we estimate that the cell must
accumulate 100–1,000 siRNAs/cell within the initial 6 hr of infec-
tion to successfully result in attenuation. These data are also
consistent with the successful self-targeting of the IAV-siNP
strain as this virus design generates 100–1,000 copies/cell within
the first 3 hr of infection (Varble et al., 2010).
To further corroborate the results for the NP self-targeted virus
strain, we generated alternate versions of this virus design where
targeting was miR-124 based. To this end, we again used a
segment eight that expressed miR-124 and coupled this to the
various segment five constructs described in Figure 1C. As antic-
ipated, all but the virus containing a scrambled (Scbl) NP 30 UTRCell Reports 13, 1456–1466, Ndemonstrated a self-targeting phenotype
resulting in a 2 or 3 log attenuation (Figures
S3A, S3B, and 3A). After passaging and
sequencing these viruses,weagain isolated
escape mutants and, as previously
observed, found them to be limited to
miRNA hairpin mutants that lost the capac-
ity to produce the siRNA. The self-targeting
virus with four siRNA-binding sites
composed of 16 nt of complementary
(16x4) generated a segment whereby themiR-124 hairpin contained six nt deletions dispersed throughout
the hairpin (Figure 3B). This mutated strain (herein referred to as
16x4 Mutant) lost the capacity to generate miR-124 and demon-
strated a replication capacity that matched wild-type virus (Fig-
ures 3C and 3D). Comparably, passaging a self-targeting virus
with four siRNA-binding sites composed of 20 nt of complemen-
tarity also generated anescapemutant. Thismutant (20x4Mutant)
excised the complete hairpin and also demonstrated the loss of
miR-124 and self-induced viral attenuation (Figures 3E and 3F).
Next, to further address the role of the intrinsic antiviral
response and NS1 antagonistic function during self-targeting,
we repeated similar studies in wild-type murine embryonic fibro-
blasts (MEFs) and MEFs lacking interferon regulatory factors 3
and 7 (Irf3//Irf7/), which are essential for the establishment
of the antiviral response (Daffis et al., 2009). To this end, we in-
fected WT and double knockout cells with either self-targeting
or control viruses encoding either wild-type NS1 or an RNA-
binding mutant of NS1 (herein referred to as mNS1; Donelan
et al., 2003) and ascertained silencing potential (Figures 3G
and 3H). Infection of MEFs with either IAV or IAV-124 yieldedovember 17, 2015 ª2015 The Authors 1459
Figure 3. Determining the Role of NS1
during Self-Targeting
(A) Multi-cycle growth in MDCK cells infected
(MOI = 0.01) with the corresponding viruses.
Supernatants were collected 24 hpi and plaqued
on MDCK cells. Error bars represent SD; *p < 0.05.
(B) Schematic depicting the hairpin in the parental
virus (top) and themutant virus (bottom). The siRNA
against NP (siNP) is depicted in red.
(C) Northern blot of MDCK cells infected with IAV,
16x4 mutant, or 16x4 control viruses. Top panel
depicts miR-124, and lower shows U6 as loading
control.
(D) Virus titers from MDCK cells infected with the
viruses in (C).
(E) Northern blot of MDCK cells infected with IAV,
20x4 mutant, or 20x4 control viruses. Top panel
depicts miR-124, and lower shows U6 as loading
control.
(F) Virus titers from MDCK cells infected with the
viruses in (E). Error bars represent SD; *p < 0.05.
(G) Virus titers from WT or Irf3//Irf7/ MEFs
infected (MOI = 1) with IAV, IAV-124, mIAV-124,
IAV-124t/wtNS-124, and IAV-124t/mNS-124.
Supernatants were collected 24 hpi and plaqued
on MDCK cells. Error bars represent SD; *p < 0.05.
(H) Fold titer of the viruses used in (G). Error bars
represent SD; *p < 0.05.comparable titers of 105 pfu/ml and 106 pfu/ml in wild-type and
Irf3//Irf7/ cells, respectively, supporting established find-
ings that NS1 effectively antagonizes IRF signaling and that
miRNA inclusion does not impact IAV replication in vitro
(Garcı´a-Sastre et al., 1998; Varble et al., 2010). This latter
concept could be further corroborated in vivo, as titers of IAV
and IAV-124 were indistinguishable in mice at 2 days postinfec-
tion (Figure S3C).
In agreement with past studies (Donelan et al., 2003), we also
found that loss of NS1 function significantly impaired virus repli-
cation in wild-type cells but replicated to comparable titers as
wild-type virus in the absence of an IRF3/7-dependent antiviral
response (Figure 3G). Next, to address a report that has sug-
gested NS1 antagonizes small RNA silencing (Li et al., 2004),
we compared self-targeting in these two in vitro systems with vi-1460 Cell Reports 13, 1456–1466, November 17, 2015 ª2015 The Authorsruses encoding either wild-type or the
RNA-bindingmutant of NS1. In agreement
with the results obtained from our siNP-
and 124-based self-targeting viruses, we
found that NS1 functionality had minimal
impact on the extent of attenuation when
the IRF-mediated defenses of the cell
are eliminated. Comparing genotype-
matched viruses to their self-targeting
counterparts, encoding either wild-type
or mutant NS1, demonstrated an 20- to
50-fold loss of virus titers during a single
cycle of replication in the absence of the
intrinsic antiviral cell response (Figure 3H).
Interestingly, in an environment when anti-viral RNAi was enabled in parallel with a functional IFN-I system,
virus titers demonstrated an 50- to 100-fold loss, suggesting
the two pathways can complement each other. Taken together,
these results illustrate the effectiveness of small RNA silencing
as an antiviral mechanism and suggest that neither NS1 nor the
IFN-I response dramatically disrupt the processing, loading, or
silencing potential of small RNAs.
Species-Specific miRNA-Mediated Attenuation of IAV
In an effort to generate an attenuated virus that was unchanged
at the protein level but could be inhibited independently of the
intrinsic defenses of mammalian cells, we incorporated five
unique miRNA targets sites into the NP transcript encoded
from segment five. In an effort to maintain the capacity to
grow the virus, we chose to exploit mammalian-specific
miRNAs to permit uninhibited replication in eggs. To this end,
Figure 4. Engineered Antiviral RNAi Can Potently Inhibit Virus
Replication in Mammals
(A) Western blot of extracts derived from NoDice cells infected (MOI = 0.1) with
IAV, IAV-Scbl, or with increasing amounts of the NP-targeted viruses (IAV-NPt)
for 24 hr. Top panel depicts NS1, and the lower panel shows NP and actin as a
loading control. Bracketed values represent egg infectious dose 50 (EID50)
units for Scbl and IAV-NPt.
(B) Multi-cycle growth curve in A549s cells infected (MOI = 0.01) with the
viruses used in (A). Supernatants were collected 12, 24, 36, and 48 hpi and
plaqued on MDCK cells. LOD denotes the level of detection.
(C) Western blot of extracts derived from A549 cells infected (MOI = 0.1) with
the viruses in (A). Lysates were collected 10 and 20 hpi and blotted for NP and
actin.we incorporated miR-93 and -192 targets as previously
described (Langlois et al., 2013; Perez et al., 2009) in addition
to individual targets for miR-21, -31, and -29b, which small
RNA deep sequencing identified as being low in embryonated
eggs but high in human and mouse lung (Perez et al., 2009).
Upon confirming differential expression of miR-21, -31,
and -29b (Figure S4A), we inserted individual target sites as an
artificial 30 UTR of NP as previously described (Langlois et al.,
2012). As a control, we also generated a virus containing five tan-
dem targets (corresponding to a position in theORF of EGFP that
was previously targeted by an artificial miRNA; Varble et al.,
2013). In agreement with past studies, the egg-derived stocks
of virus demonstrated indistinguishable hemaggluttination (HA)
activity, presumably owing to the absence of the aforementioned
miRNAs (Figure S4B). In contrast, attempts to quantify virus by
standard plaque assay in MDCK cells revealed that the
miRNA-targeted strain failed to produce plaques, even when
NP was probed with an antibody in place of standard crystalCell Repviolet staining (data not shown). As a result, we determined the
egg infectious dose (EID) to infect 50% of the eggs (EID50)
for both the control and targeted strains and used this to esti-
mate pfus based on the control virus standards. These data
suggested the miRNA-targeted virus grew comparably in eggs
(2 3 105 EID50/ml as compared to 6 3 10
5 EID50/ml for the
control strain, corresponding to approximately 1 3 105 pful/ml
and 3 3 105 pful/ml, respectively). These titers could also be
corroborated by semiquantitative western blot in cells lacking
Dicer (Figure 4A).
In an effort to better characterize the replication properties of
the miRNA-targeted strain, we performed multi-cycle growth
curves in A549 cells and measured titers at 12, 24, 36, and 48 hr
postinfection (Figure 4B). Interestingly, whereas the control and
parental viruses replicated to the same titers with comparable ki-
netics, the NP-targeted virus failed to produce a single plaque or
demonstrate HA activity (Figures 4B and S4C). These data could
be further corroborated by western blot, demonstrating a com-
plete lack of NP expression (Figure 3C). Taken together, these
results illustrate the silencingpotential ofmiRNA-mediated target-
ing to attenuate virus infection in vitro in a host-specific manner.
Assessing miRNA-Mediated Virus Attenuation In Vivo
In an effort to ascertain whether miRNA-mediated virus attenua-
tion maintained its in vitro potency in vivo, we administered
6-week-old C57BL/6mice intranasally with 250 pfu of the control
and targeted viruses and monitored morbidity (Figure 5A). Given
that the 50% lethal dose (LD50) of the wild-type virus is 50 pfu,
inoculation of 5 LD50 of the control virus resulted in dramatic
weight loss, ultimately leading to 100% mortality (Figure 5A). In
contrast, the miRNA-targeted strain demonstrated no signs of
morbidity or mortality at this inoculating dose or at doses of
2,500 and 25,000 pfus (Figure 5A). Moreover, H&E staining
of lungs derived from mice infected with 250 pfu of the miRNA-
targeted strain demonstrated no signs of inflammation or dam-
age at either 2 or 9 days postinfection (Figure 5B). In contrast,
the same treatment with untargeted IAV found severe lesions
in the bronchiolar epithelium consistent with highly virulent vi-
ruses with additional evidence for focal perivascular and alveolar
edema at both time points monitored (Figure 5B).
Finally, in an effort to determine whether mammals could have
maintained the evolutionary usage of antiviral small RNAs in
place of our IFN-I system, we characterized our virus strains in
the context of Ifnar1/ mice. To this end, we treated knockout
mice in a manner identical to that performed in wild-type ani-
mals, administrating 250, 2,500, or 25,000 pfus of the miRNA-
targeted strain intranasally (Figure 5C). Remarkably, these data
found that, even at a dose of 25,000 pfus (a dose more than
2,500 times greater than the LD50; Koerner et al., 2007), there
were no signs of morbidity or mortality despite the absence of
IFN-I signaling. Consistent with these findings, virus transcripts
on day 2 showed no detectable levels of virus mRNA (Fig-
ure S5A). Attenuation in both WT and Ifnar1/ mice could be
further confirmed at both days 2 and 9 postinfection by NP-
based plaque assays (Figures S5B and S5C).
miRNA-Mediated Attenuation Can Elicit Antiviral
Protection that Negates the Requirement for IFN-I
To better ascertain how the intrinsic and adaptive antiviral re-
sponses are coordinated under conditions where small RNAorts 13, 1456–1466, November 17, 2015 ª2015 The Authors 1461
Figure 5. In Vivo Demonstration of Small-
RNA-Mediated Attenuation of Virus in Both
Wild-Type and IFN-Defect Animals
(A) Graph depicting change in body mass of C57BL
mice following intranasal inoculation with PBS, IAV,
or IAV-NPt. Error bars represent SD; *p < 0.05.
(B) Histology of lungs frommice infected with IAV or
IAV-NPt. Lungs were harvested 2 and 9 dpi,
sectioned, and slides were stained with H&E.
(C) Graph depicting change in body mass of
Ifnar1/ mice following intranasal inoculation with
PBS, IAV, or IAV-NPt. Error bars represent SD;
*p < 0.05.silencing has replaced the intrinsic antiviral defenses of the cell,
we next used RNA-seq to compare and contrast the host tran-
scriptome to infection in either the presence or absence of the
IFN-I response (Figures 6A and 6B). Strikingly, comparing
mock-treated mice to either the scrambled control or the
miRNA-targeted strain illustrated the potency of small-RNA-
mediated attenuation. In response to the untargeted strain, the
host showed a robust induction of canonical ISGs (Figure 6A).
For example, levels of myxovirus resistance 1 (Mx1) were
induced more than 40-fold in response to the control virus
but only 2-fold in response to the miRNA-targeted strain
(Table S1). Additional canonical ISGs, such as Ifit1, Oas1b,
Oas2, and Isg15 were induced 10-fold in response to the con-
trol infection but remained at baseline levels in response to the
miRNA-targeted virus. These trends were also evident at day 9
and included chemokines such as Ccl12, Cxcl10, Cxcl9,
Cscl11, Cxcl13, Ccr5, Ccr1, and Ccl4 (Table S1).
The antiviral transcriptional response observed in C57BL6
mice was significantly muted when the same experiment was
performed in Ifnar1/ mice (Figure 6B). Profiling of mRNA in
these mice demonstrated the diminished antiviral response
that occurs in the absence of any feedback loop elicited by
IFN-I signaling. For example, Mx1 levels demonstrated only a
3-fold induction in response to wild-type virus infection 48 hr
postinfection (Table S2). Comparable to the transcriptional
profiling in wild-typemice, the response in Ifnar1/ also demon-
strated amuted response following administration of themiRNA-
targeted strain. However, in this analysis, differential expression
of ISGs between the two experimental cohorts was less pro-
nounced with genes such as Ifit1. This result is not surprising
given that many ‘‘ISGs’’ can also be induced directly in response
to the activation of IRF3 and/or IRF7 (Schmid et al., 2010). The1462 Cell Reports 13, 1456–1466, November 17, 2015 ª2015 The Authorsmodest induction of known IRF-mediated
antiviral genes on day 2 suggests that the
intrinsic cellular response to either wild-
type or miRNA-targeted viruses was
comparable—showing an 5-fold induc-
tion of antiviral transcription factors
(i.e., Stat1), antiviral effectors (i.e., Oas
and Isg15), and proinflammatory cyto-
kines (i.e., Cxcl9, Ccl4, and Ccl7). In
contrast, on day 9, the elevated levels of
these antiviral transcripts remain high inresponse to untargeted virus yet are completely absent following
infection with the miRNA-targeted strain. Whereas this trend is
evident for the complete antiviral transcriptome, it is most strik-
ing with regards to the proinflammatory cytokines, suggesting
miRNA-targeted strains did not induce sustained inflammation.
Furthermore, qPCR analysis of IAV matrix demonstrated that
wild-type viruses had not been completely cleared by day 9 in
either wild-type or Ifnar1/mice in contrast to the virus targeted
via RNAi, which yielded only background levels under all condi-
tions tested (Figures S6A andS6B). In all, these data suggest that
a small RNA-mediated antiviral defense strategy can effectively
replace the intrinsic protein-based response normally utilized
by mammals.
DISCUSSION
The capacity to inhibit virus infection using pathogen-derived
small RNAs has proven an effective strategy in both prokaryotes
and eukaryotes (tenOever, 2013). Whereas it remains unknown
whether we replaced an ancient RNAi-based antiviral response
with something that was more suited to our evolutionary needs,
it is clear that mammals predominantly utilize a cytokine-based
system that relies on paracrine signaling and the upregulation
of hundreds of antiviral effector proteins (Schoggins et al.,
2011). Here, we attempt to determinewhether there is something
unique to mammals that precludes our use of a small RNA anti-
viral defense system by recreating a comparable environment in
mice. Interestingly, by exploiting the presence of host- or virus-
derived siRNAs, we can demonstrate potent attenuation that im-
poses a strong selective pressure and fails to generate virus
escape mutants, even in the complete absence of an IFN-I
response.
Figure 6. Attenuation of miRNA-Mediated
Viruses Does Not Require the Intrinsic Anti-
viral Response
Heatmaps depicting the transcriptomes of WT or
Ifnar1/ mice infected for 2 and 9 days with IAV or
the IAV-NPt viruses based on biological replicates
of RNA-seq data.Given the evolutionary success of the RNAi-mediated antiviral
platform, thequestion remains as towhymammalsdonot employ
a small RNA-based strategy to inhibit virus infection. There is
strong circumstantial evidence that self-replicating RNAs were
necessary for the emergence of life and that these virus-like ele-
ments would have therefore evolved with the earliest common
ancestors before branching off into prokaryote- and eukaryote-
specific lineages (Prangishvili et al., 2006; Rice et al., 2004). It
therefore seems a fair assumption that all life required a common
means of responding to these pathogenic RNA elements. As our
origins stem from prokaryotes, this would further imply that our
defenses at one time involved coupling a nuclease to a specific
pathogen-derived sequence, general themes observed in both
the CRISPR and RNAi systems. Interestingly, whereas germline
cells have a CRISPR-like activity in the form of piRNAs to combat
transposable elements, the general response to virus infection in
all other cells is quite distinct (Loo and Gale, 2011).
Explanations for why mammals do not utilize RNAi are
numerous. Arguably the most-logical explanation would be
that strong selective pressure imposed by the capacity to inhibit
RNAi may have accelerated the emergence of a new antiviral
strategy. Interestingly, mammalian viruses have been suggested
to encode suppressors of RNAi (Guo and Steitz, 2014). Among
RNA viruses, Flock House virus, Nodavirus, Ebola virus, and
IAV have all been suggested to inhibit small-RNA-mediated
silencing (Fabozzi et al., 2011; Li et al., 2004, 2013; Maillard
et al., 2013). Whereas this work cannot speak to the claims ofCell Reports 13, 1456–1466, Nthe Nodaviridae or Ebola virus antagonistic
activity, we do not find that the NS1 protein
of IAV is an effective inhibitor of small-
RNA-mediated silencing. Whereas we do
note that attenuation of a self-targeting vi-
rus was marginally elevated when
comparing wild-type and mutant NS1 ge-
notypes, the small difference in targeting
efficiency is unlikely to reflect direct antag-
onism of this pathway but rather is more
likely due to an unrelated mechanism
such as increased defective interfering
particles that form in the absence of a
functional NS1. This is supported by inde-
pendent studies that found NS1 overex-
pression had no impact on RNAi activity
in mammalian cells in the presence or
absence of virus infection (Perez et al.,
2009). It should also be noted that Ebola vi-
rus infections have been successfully
treated, even 3 days postinfection, with
exogenous delivery of siRNAs (Thi et al.,2014, 2015). Taken together, these results suggest that, should
these viruses have some capacity to block the RNAi response,
viruses such as these would be unlikely to exert the type of evo-
lution pressure needed to demand the emergence of the IFN-I
system. In contrast, many RNA viruses readily escape RNAi tar-
geting and thus do not require a mechanism to inhibit such a
response. Experiments applying exogenous siRNAs as a means
to treat virus infection, whereas generally effective, often result in
the emergence of escape mutants (Barnes et al., 2008; Boden
et al., 2003; Das et al., 2004; Gitlin et al., 2002; Heiss et al.,
2011, 2012; Teterina et al., 2014; Wilson and Richardson,
2005). Whereas virus escape was sometimes the result of an
excision event (Pham et al., 2012), in general, single mutations
in a given small RNA target were sufficient to relieve silencing
(van Rij and Andino, 2006). For viruses such as poliovirus, which
encodes an error-prone RNA-dependent RNA polymerase
(RdRp), a spectrum of viruses encoding numerous single muta-
tions is generated at every round of infection, inevitably allowing
for escape of RISC-mediated silencing (Gitlin et al., 2005). Given
this, an error-prone RNA virus might provide the evolutionary
pressure needed to select for the emergence of the IFN-I system.
In contrast to RNA viruses, there is strong evidence that DNA
viruses encode antagonists to the small-RNA-silencing path-
ways of mammals. DNA viruses that disrupt aspects of miRNA
biology include poxviruses (Backes et al., 2012), adenoviruses
(Lu and Cullen, 2004), and herpesviruses (Cazalla et al., 2010).
Given these dynamics, one could envision that perhaps a DNAovember 17, 2015 ª2015 The Authors 1463
pathogen in our evolutionary past rendered our RNAi response
ineffective and thus would have demanded an evolutionary
need for the emergence of IFN-I.
Lastly, it is possible that the intrinsic response to virus infection
in chordates never included small RNAs. This concept is sup-
portedby the lackof evolutionaryduplicationwith regards tocom-
ponents of the small RNA machinery. In contrast to mammals,
plants show evidence of many Dicer-like proteins, each one
with the unique capacity to recognize specific virus genomes
(Xie et al., 2004) much like the expansion of IRFs and/or IFN alpha
loci in many chordate species (Langevin et al., 2013; Manry et al.,
2011). Furthermore, given the necessity to generate high levels of
siRNAs in a very short time period, it would seem that chordates
would also require an RdRp to amplify virus-derived small RNAs
and an RNA transporter to provide systemic protection. Interest-
ingly, whereas chordates do express a homolog of SID-1 (sys-
temic RNAi defective 1), a gene product responsible for small
RNA movement between cells, we do not express an RdRp
(Jose and Hunter, 2007). Whereas the function of SID-1 in mam-
mals remains unknown, expression of an exogenous RdRp has
been associated with the induction of IFN-I, suggesting these
two systems may be inherently incompatible (Yu et al., 2012).
Regardless of the RNAi history in chordate biology, it is clear
that the small RNAmachinery ofmammalian cells has the capac-
ity to potently target RNA viruses when exploited. Whereas this
may be universally true for all viruses, one possible explanation
for the emergence of the more-general IFN-I response could
have derived from pathogens whose biology is not amenable
to small RNA targeting. For example, present day pathogens
such as malaria and cholera have been implicated in imposing
strong selective pressure in humans in a very short evolutionary
time span (Siddle and Quintana-Murci, 2014), so perhaps it was
an ancient protozoan or bacterium of early chordates that
rendered the specificity of the RNAi response useless and de-
manded the emergence of the more-general IFN-I response.
Whereas finding answers to such evolutionary questions are
near impossible to address, what is clear based on this study
is that mammals could have utilized RNAi in place of IFN-I and
that the existing machinery can be exploited for therapeutic
benefit.
EXPERIMENTAL PROCEDURES
Virus Engineering and Generation
HEK293T cells were transfected with plasmids expressing bidirectional vRNA
andmRNAaspreviously described (Hoffmann et al., 2000). All of the constructs
encode for components of A/PuertoRico/8/34 (H1N1). To generate the self-tar-
geted viruses, a modified NS segment was used, which has been described
elsewhere (Varble et al., 2010). Viruses encoding self-targeting siRNAs were
rescued in NoDice cells (Bogerd et al., 2014b). Cells were collected 48 hr post-
transfection and injected into the allantoic fluid of 8-day-old embryonated
eggs. Allantoic fluid was extracted 48 hr postinjection, and viruses were quan-
tified by hemagglutinin assay using chicken red blood cells (Lampire Biological
Pharmaceuticals) in Alsevers and titteredbyplaque assay onMDCKcells. Influ-
enza plaque assays were performed with media containing EMEM (Lonza),
L-glutamine (Corning), NaHCO3, BSA, and 2% agar (Oxoid).
Small-RNA Northern Blot
Total RNA was harvested at the indicated time points using the Trizol method,
and northern blotting was performed as previously described (Pall and Hamil-1464 Cell Reports 13, 1456–1466, November 17, 2015 ª2015 The Auton, 2008). The following probes were used: anti-miR-21: TCAACATCAGTCT
GATAAGCTA; anti-miR-31: AGCTATGCCAGCATCTTGCCT; miR-29b: AACA
CTGATTTCAAATGGTGCTA; anti-miR-192: GGCTGTCAATTCATAGGTCAG;
anti-miR-93: CTACCTGCACGAACAGCACTTTG; anti-miR-124: TGGCATT
CACCGCGTGCCTTAA; anti-siNP: GCATTTGAAGATCTAAGAGTA; and
anti-U6: GCCATGCTAATCTTCTCTGTATC.
Deep Sequencing
mRNA-seq libraries were prepared using 1 mg total RNA. The TruSeq RNA
Library Preparation Kit v2 was used according to the manufacturer’s instruc-
tions. Briefly, mRNA was purified via oligo-dT beads, fragmented, and reverse
transcribed with SuperScript II (Invitrogen), followed by second strand synthe-
sis, end repair, A-tailing, and adaptor ligation. Quantification of barcoded sam-
ples and pooled libraries were assessed using the Universal complete KAPA
Library Quantification Kit (KAPA Biosystems). Pooled libraries were run on
either an Illumina MiSeq platform using the MiSeq Reagent Kit v3 (Illuminia)
or an Illumina HiSeq. Read mapping, statistical analysis, and dot plot genera-
tion was preformed using BaseSpace RNA Express application (Illumina). The
publicly available platform http://www.interferome.org/interferome/home.jspx
was used to select the ISGs displayed in the heatmaps. RNA-seq results were
visualized using the Microarray Software Suite TM4 (http://www.tm4.org/mev.
html).
In Vivo Infections
Six- to eight-week-old C57BL/6 mice (either wild type or Ifnar1/) were anes-
thetized with ketamine/xylazine and intranasally administered virus in 50 ml of
PBS. Lungswere extracted at time points indicated and homogenized in 700 ml
PBS supplemented with protease inhibitor. Total RNA extraction from homog-
enized tissue was performed by standard Trizol extraction. All experiments
involving animals were performed in accordance with the Icahn School of
Medicine Animal Care and Use Committee.
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